The month ahead: January’s remaining events
JP Morgan approaches.
Incyte does TGF-beta differently
Four months after yielding first-in-human data INCA33890 enters phase 3.
FDA red and green lights: December 2025
Seven oncology approvals included nods for subcutaneous Rybrevant and Lunsumio.
GSK makes haste while Daiichi struggles
Mocertatug rezetecan is starting its first western pivotal trials.
Another in vivo Car speeds into the clinic
PersonGen’s LV009 takes the industry tally of clinical-stage projects to 14.
Corcept tries to repeat the glucocorticoid trick
Nenocorilant features among the latest industry projects newly into phase 1.
Henlius and Ottimo join the bispecific bundle
Two new PD-(L)1 x VEGF projects have entered the clinic.
